Prognostic influence of loss of blood group A antigen expression in pathologic stage I non-small-cell lung cancer
Arch Bronconeumol. 2012 Feb;48(2):49-54.
doi: 10.1016/j.arbres.2011.10.003.
Epub 2011 Dec 5.
[Article in
English,
Spanish]
Authors
Pablo León-Atance
1
, Nicolás Moreno-Mata, Federico González-Aragoneses, Miguel Ángel Cañizares-Carretero, Enrique Poblet-Martínez, Marta Genovés-Crespo, María Dolores García-Jiménez, Antonio Francisco Honguero-Martínez, Carlos Alberto Rombolá, Carlos María Simón-Adiego, Rafael Peñalver-Pacual, Emilio Alvarez-Fernández
Affiliation
- 1 Sección de Cirugía Torácica, Complejo Hospitalario Universitario de Albacete, Albacete, España. pabl1150@separ.es
Abstract
Introduction:
In the scientific literature, contradictory results has been published on the prognostic value of the loss of expression of blood group antigen A (BAA) in lung cancer. The objective of our study was to analyze this fact in our surgical series.
Patients and methods:
In a multicenter study, 402 non-small-cell lung cancer (NSCLC) patients were included. All were classified as stage-I according to the last 2009-TNM classification. We analyzed the prognostic influence of the loss of expression of BAA in the 209 patients expressing blood group A or AB.
Results:
The 5-year cumulative survival was 73% for patients expressing BAA vs 53% for patients with loss of expression (P=.03). When patients were grouped into stages IA and IB, statistical significance was only observed in stage I-A (P=.038). When we analyzed the survival according to histologic type, those patients with adenocarcinoma and loss of expression of BAA had a lower survival rate that was statistically very significant (P=.003). The multivariate analysis showed that age, gender and expression of BAA were independent prognostic factors.
Conclusions:
The loss of expression of blood group antigen A has a negative prognostic impact in stage I NSCLC, especially in patients with adenocarcinoma.
Copyright © 2011 SEPAR. Published by Elsevier Espana. All rights reserved.
MeSH terms
-
ABO Blood-Group System / metabolism*
-
Adenocarcinoma / chemistry
-
Adenocarcinoma / enzymology
-
Adenocarcinoma / mortality
-
Adenocarcinoma / pathology
-
Adenocarcinoma / surgery
-
Aged
-
Aged, 80 and over
-
Antigens, Neoplasm / metabolism*
-
Carcinoma, Non-Small-Cell Lung / chemistry
-
Carcinoma, Non-Small-Cell Lung / enzymology*
-
Carcinoma, Non-Small-Cell Lung / mortality
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Carcinoma, Non-Small-Cell Lung / surgery
-
Chromosome Deletion*
-
Chromosomes, Human, Pair 9 / genetics*
-
DNA Methylation*
-
Female
-
Gene Deletion*
-
Humans
-
Immunoenzyme Techniques
-
Lung Neoplasms / chemistry
-
Lung Neoplasms / enzymology*
-
Lung Neoplasms / mortality
-
Lung Neoplasms / pathology
-
Lung Neoplasms / surgery
-
Male
-
Middle Aged
-
N-Acetylgalactosaminyltransferases / deficiency*
-
N-Acetylgalactosaminyltransferases / genetics
-
N-Acetylgalactosaminyltransferases / metabolism
-
Neoplasm Proteins / deficiency*
-
Neoplasm Proteins / genetics
-
Neoplasm Proteins / metabolism
-
Neoplasm Staging
-
Pneumonectomy
-
Prognosis
-
Retrospective Studies
Substances
-
ABO Blood-Group System
-
Antigens, Neoplasm
-
Neoplasm Proteins
-
N-Acetylgalactosaminyltransferases
-
UDPgalactosamine-galactose acetylgalactosaminyltransferase